Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: BUY (auto-tracking)
-3.95% $76.69
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 7 424.14 mill |
EPS: | -1.460 |
P/E: | -52.53 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 96.81 mill |
Avg Daily Volume: | 0.851 mill |
RATING 2024-04-17 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -52.53 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.10x |
Company: PE -52.53 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 74.37 - 79.01 ( +/- 3.03%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Van Nostrand Robert L | Buy | 79 | Common Stock |
2024-03-31 | Riggs Rory B | Buy | 260 | Common Stock |
2024-03-20 | Riggs Rory B | Buy | 20 000 | Common Stock |
2024-03-20 | Riggs Rory B | Sell | 20 000 | Stock Option (right to buy) |
2024-03-10 | Mates Sharon | Buy | 20 565 | Common Stock |
INSIDER POWER |
---|
-0.64 |
Last 100 transactions |
Buy: 514 872 | Sell: 520 193 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $76.69 (-3.95% ) |
Volume | 2.52 mill |
Avg. Vol. | 0.851 mill |
% of Avg. Vol | 296.68 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $71.42 | N/A | Active |
---|
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.